$BNOX News

Last published 1y ago

1y agoBNOXBionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-DomiciliationGlobeNewswireADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia ("Court")
1y agoBNOXResults of Scheme MeetingGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed
1y agoBNOXBionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM EvidenceGlobeNewswireBNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2 2025 ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024
1y agoBNOXBionomics to Present at the 2024 American College of Neuropsychopharmacology Annual MeetingGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
1y agoBNOXBionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United StatesGlobeNewswireADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics Provides an Update on Re-domiciliation via Scheme of ArrangementGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics to Present at the 2024 CNS SummitGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology ProgramGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics to Present at the ThinkEquity ConferenceGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic VisionGlobeNewswireADELAIDE, Australia, and CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics Limited announces intention to re-domicile to the United StatesGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company"), a clinical-stage biotechnology company developing novel, potential
2y agoBNOXBionomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress DisorderGlobeNewswireSuccessful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder (PTSD) with a single
2y agoBNOXBionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024GlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety DisorderGlobeNewswireTopline results are expected in Q3 2025 ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a biotechnology company developing novel,
2y agoBNOXBionomics Limited Announces Private Placement of up to $70.0 MillionGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company"), a clinical-stage biotechnology company developing novel, potential
2y agoBNOXBionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual MeetingGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion
2y agoBNOXBionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress DisorderGlobeNewswireBNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.
2y agoBNOXBionomics to Present at the 2024 BIO CEO & Investor ConferenceGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics Provides a Review of 2023 and of 2024 PlansGlobeNewswirePositive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration
2y agoBNOXBionomics to Present at Biotech Showcase™ 2024GlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
2y agoBNOXBionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual MeetingGlobeNewswireA psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for evaluation of social anxiety.SUDS will be used as the primary outcome in
3y agoBNOXBionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety DisorderGlobeNewswirePositive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety DisorderCompany confirms agreement with the
3y agoBNOXBionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)GlobeNewswireATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements
3y agoBNOXBionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSDGlobeNewswireBionomics has collaborated with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders like Alzheimer's DiseaseBased on the learnings from Bionomics' candidate BNC375, additional candidates
3y agoBNOXBionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210GlobeNewswireThe last patient last visit has been completed in the Phase 2b ATTUNE study of BNC210 for the treatment of PTSDTopline results from Phase 2b ATTUNE study of BNC210 in patients with PTSD are expected by the end of
3y agoBNOXQuarterly Activities and Cashflow ReportGlobeNewswireADELAIDE, Australia, and CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,
3y agoBNOXBionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)GlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX:BNO, NASDAQ:BNOX) (Bionomics or the Company) a clinical-stage biotechnology company developing novel, first-in-class,
3y agoBNOX ORGOBionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic GrowthGlobeNewswireAlan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX:
3y agoBNOXBionomics to Present at Upcoming June Investor ConferencesGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class,
3y agoBNOXBionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual MeetingGlobeNewswireADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion
3y agoBNOXQuarterly Activities and Cashflow ReportGlobeNewswireADELAIDE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO, )), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel
3y agoBNOXBionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)GlobeNewswireADELAIDE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators
3y agoBNOXBionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)GlobeNewswireBoth doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of the full data set and
3y agoBNOXBionomics' Half-Year ReportGlobeNewswireADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX: BNO, NASDAQ:BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational
3y agoBNOXQuarterly Activities and Cashflow ReportGlobeNewswireADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO, )), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel
3y agoBNOXBionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety DisorderGlobeNewswireBNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to PlaceboBNC210
3y agoBNOXBionomics appoints Spyridon "Spyros" Papapetropoulos as President and Chief Executive OfficerGlobeNewswireADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel
3y agoBNOXBionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual MeetingGlobeNewswireADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators
3y agoBNOXBionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United StatesGlobeNewswireADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX: BNO, NASDAQ:BNOX), ("Bionomics" or the "Company"), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel
3y agoBNOXBionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United StatesGlobeNewswireADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX: BNO, NASDAQ:BNOX), ("Bionomics" or the "Company"), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel
4y agoBNOXBionomics Limited to Participate in Upcoming November Investor ConferencesGlobeNewswireADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators
4y agoBNOXQuarterly Activities Report for September 2022GlobeNewswireADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX: BNO, NASDAQ:BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel
4y agoBNOXBionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 millionGlobeNewswireADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO)) (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received
4y agoBNOXBionomics Limited to Participate in the Cantor Neurology & Psychiatry ConferenceGlobeNewswireADELAIDE, Australia, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of
4y agoBNOXBionomics to Host KOL Webinar on BNC210 and Social Anxiety DisorderGlobeNewswireADELAIDE, Australia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of
4y agoBNOXBionomics to Participate in Upcoming September Investor ConferencesGlobeNewswireADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients su
4y agoBNOXBionomics reports Full Year Financial ResultsGlobeNewswireADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX:BNO, NASDAQ:BNOX), today announced its financial results for the 12 months ended 30 June 2022. Bionomics is a clinical stage biopharmaceutical company developing novel, a
4y agoBNOXBionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1MGlobeNewswireADELAIDE, Australia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX: BNO, NASDAQ:BNOX), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$2,085,453.17 research and development (R&D) tax incent